CN115667190A - 双环类化合物及其应用 - Google Patents

双环类化合物及其应用 Download PDF

Info

Publication number
CN115667190A
CN115667190A CN202180037613.0A CN202180037613A CN115667190A CN 115667190 A CN115667190 A CN 115667190A CN 202180037613 A CN202180037613 A CN 202180037613A CN 115667190 A CN115667190 A CN 115667190A
Authority
CN
China
Prior art keywords
dihydro
tetrafluoro
difluoromethyl
oxy
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037613.0A
Other languages
English (en)
Inventor
杨荣文
孙云
张赟
王萍萍
兰宏
丁列明
王家炳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN115667190A publication Critical patent/CN115667190A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/08—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring
    • C07C13/10—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring with a cyclopentane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/20—Polycyclic condensed hydrocarbons
    • C07C15/24—Polycyclic condensed hydrocarbons containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C23/00—Compounds containing at least one halogen atom bound to a ring other than a six-membered aromatic ring
    • C07C23/02—Monocyclic halogenated hydrocarbons
    • C07C23/08—Monocyclic halogenated hydrocarbons with a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings

Abstract

提供一种如式(I)所示的化合物，包含这类化合物的组合物和制剂，及使用和制备该类化合物的方法。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180037613.0A 2020-06-17 2021-06-17 双环类化合物及其应用 Pending CN115667190A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020105532024 2020-06-17
CN202010553202 2020-06-17
PCT/CN2021/100491 WO2021254417A1 (zh) 2020-06-17 2021-06-17 双环类化合物及其应用

Publications (1)

Publication Number Publication Date
CN115667190A true CN115667190A (zh) 2023-01-31

Family

ID=79268481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037613.0A Pending CN115667190A (zh) 2020-06-17 2021-06-17 双环类化合物及其应用

Country Status (2)

Country Link
CN (1) CN115667190A (zh)
WO (1) WO2021254417A1 (zh)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002742A1 (de) * 1977-12-22 1979-07-11 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Stilbenderivate, ihre Herstellung und Arzneimittel enthaltend diese Stilbenderivate
WO2011035941A1 (en) * 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
CN105530923A (zh) * 2013-09-09 2016-04-27 佩洛通治疗公司 芳基醚及其用途
WO2016145032A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2017180769A1 (en) * 2016-04-13 2017-10-19 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
CN109836385A (zh) * 2019-04-04 2019-06-04 上海翰森生物医药科技有限公司 四氢喹啉类n-氧化衍生物及其制备方法和应用
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TW201927792A (zh) * 2017-12-20 2019-07-16 大陸商貝達藥業股份有限公司 作為溴結構域蛋白質抑制劑的化合物和組合物
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144825A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
TW202003430A (zh) * 2018-03-28 2020-01-16 美商佩樂敦治療公司 以ＨＩＦ-２-α之抑制劑降低消化系統發炎之方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002742A1 (de) * 1977-12-22 1979-07-11 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Stilbenderivate, ihre Herstellung und Arzneimittel enthaltend diese Stilbenderivate
WO2011035941A1 (en) * 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
CN105530923A (zh) * 2013-09-09 2016-04-27 佩洛通治疗公司 芳基醚及其用途
WO2016145032A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2017180769A1 (en) * 2016-04-13 2017-10-19 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
TW201927792A (zh) * 2017-12-20 2019-07-16 大陸商貝達藥業股份有限公司 作為溴結構域蛋白質抑制劑的化合物和組合物
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
CN109836385A (zh) * 2019-04-04 2019-06-04 上海翰森生物医药科技有限公司 四氢喹啉类n-氧化衍生物及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SONG T, ET AL: "MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells", ASIAN PAC J CANCER PREV, vol. 12, no. 5, 31 May 2011 (2011-05-31), pages 1307 - 1131 *
赵波等: ".HIF1α调控TRPC6通道在肾小球系膜细胞缺氧损伤中的分子机制", 中国中西医结合肾病杂志, vol. 19, no. 8, 20 August 2018 (2018-08-20), pages 668 - 671 *

Also Published As

Publication number Publication date
WO2021254417A1 (zh) 2021-12-23

Similar Documents

Publication Publication Date Title
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN109071498B (zh) 激酶抑制剂及其制备方法和用途
EP3057962B1 (en) Hydrochloride salt form for ezh2 inhibition
KR101866706B1 (ko) 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도
TW201835070A (zh) 芳香烴受體(AhR)調節劑化合物
WO2022007979A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2009114993A1 (zh) 一类哒嗪酮类化合物及其制备方法和用途
CN110655503A (zh) 取代的***类化合物、包含其的药物组合物、其制备方法及其用途
WO2021213317A1 (zh) Hpk1抑制剂及其制备方法和用途
JP2007517787A (ja) アロイルフランおよびアロイルチオフェン
CN117126097A (zh) 双环化合物及其应用
WO2021160087A1 (zh) 喹啉基膦氧化合物及其组合物和用途
CN116134017A (zh) 双环化合物及其应用
CN115667190A (zh) 双环类化合物及其应用
CN115667202A (zh) 茚酮类化合物及其应用
WO2022148358A1 (zh) 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
AU2017238341A1 (en) Physical form of a SGR modulator
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
TW202039500A (zh) 作為c-met抑制劑之經有機磷取代之化合物及其醫療用途
US20120214846A1 (en) Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
TWI829481B (zh) 雙環吲唑糖皮質素受體拮抗劑
WO2022002100A1 (zh) 新型苯并咪唑化合物
WO2020035010A1 (zh) 苦参碱α-酮胺类化合物及其制备方法和用途
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination